Status:
COMPLETED
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer, Biliary Tract Cancer
Eligibility:
All Genders
Brief Summary
The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.
Detailed Description
Primary objective : To assess safety of Imfinzi for patients treated with Imfinzi under the approved indication in Korea Outcome Measure: * Safety (adverse event (AE), serious adverse events (SAE), ...
Eligibility Criteria
Inclusion
- Eligible for Imfinzi treatment according to the approved label
- Provision of signed and dated written informed consent by the patient or legally acceptable representative
Exclusion
- Current participation in any interventional trial
- Other off-label indications according to the approved label
Key Trial Info
Start Date :
January 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 27 2024
Estimated Enrollment :
712 Patients enrolled
Trial Details
Trial ID
NCT04068168
Start Date
January 30 2020
End Date
December 27 2024
Last Update
November 17 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anyang-si, South Korea, South Korea
2
Research Site
Bucheon-si, South Korea, South Korea
3
Research Site
Busan, South Korea, South Korea
4
Research Site
Changwon, South Korea, South Korea